This article is more than 5 years old. Information may no longer be current.

Bevacizumab shows efficacy against CNV in pathologic myopia patients

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal bevacizumab significantly improved foveal thickness and visual acuity in patients with choroidal neovascularization due to pathologic myopia, a prospective study found.

Myriam L. Hernandez-Rojas, MD, and colleagues evaluated the short-term efficacy of a 2.5 mg injection of intravitreal Avastin (bevacizumab, Genentech) in 14 patients with pathologic myopia and subfoveal CNV. These patients averaged 53.86 years of age and had a mean spherical equivalent of –13.87 ± 3.68 D, according to the study.

The researchers found that visual acuity and foveal thickness both had significantly improved at all follow-up points out to 3 months.

Visual acuity averaged 20/200 at baseline and improved to 20/100 at 2 weeks follow-up, 20/80 at 4 weeks and 20/60 at 8 and 12 weeks.

Foveal thickness averaged 385.43 µm at baseline and improved to an average of 257.64 µm at 1 month and 194.54 µm at 3 months, according to the study.

"These favorable initial results support further larger and long-term studies," the authors wrote, noting that no short-term safety concerns were identified.

The study is published in the July/August issue of Retina.